India Biosimilar Market Overview

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Growth Rate: 17.38% (2025-2033)

India biosimilar industry is growing at a rapid pace owing to the rising demand for affordable biologics and favorable regulation. Research and development and manufacturing are also fueling market growth. According to the latest report by IMARC Group, the India biosimilar market size reached USD 866.2 million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,662.9 million by 2033, exhibiting a growth rate (CAGR) of 17.38% during 2025-2033.

Download sample copy of the Report: https://www.imarcgroup.com/india-biosimilar-market/requestsample

India Biosimilar Trends and Drivers:

The market for biosimilars has grown in India. This rise occurs for a few reasons: more chronic diseases, increased health spending, and the need for affordable treatments. Biosimilars are like approved biologics. They provide a cheaper option than expensive original medicines. This makes them appealing in price-sensitive countries like India. India's pharmaceutical infrastructure supports its need for top scientists and researchers. This foundation helps India become a global hub for biosimilar development and manufacturing. Other government efforts, like the "Make in India" campaign, have boosted this sector. Supportive rules also played a part in its growth. Indian companies are meeting local demand and expanding into overseas markets. They are focusing on the U.S., Europe, and emerging economies. Right now, there’s more focus on local and global areas. This shift has led to more investment in research and development. It also means more partnerships with major companies in the global pharmaceutical sector.

Also, it is driving innovation in the Indian biosimilar market. This boosts advanced technology and new manufacturing methods. Companies are now using advanced tools like AI, machine learning, and high-throughput screening. These tools help make biosimilar development faster and more accurate. This lowers the time and cost of distributing biosimilars. So, it improves patient access. Trust grows for patients and healthcare providers when they know these medicines are safe and effective. Healthcare coverage for all, including biosimilars in national programs, is boosting growth in the Indian market. Some challenges still need attention. This includes strict rules, worries about intellectual property, and the need for strong checks after marketing. The Indian biosimilar market faces challenges, but it is still growing. Projections show it will grow over 20% each year. This growth will make India a top pharmaceutical market worldwide.

We explore the factors driving the growth of the market, including technological advancements, consumer behaviors, and regulatory changes, along with emerging India biosimilar market trends.

India Biosimilar Industry Segmentation:

The report has segmented the market into the following categories:

Molecule Insights:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

Indication Insights:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

Manufacturing Type Insights:

• In-house Manufacturing
• Contract Manufacturing

Regional Insights:

• North India
• West and Central India
• South India
• East and Northeast India

Competitive Landscape:

The competitive landscape of the industry has also been examined, along with the profiles of the key players.

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current, and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA 

Email: [email protected] 

Tel No:(D) +91 120 433 0800 

United States: +1-631-791-1145